Join our daily newsletter At The Bell to receive exclusive market insights
- Exopharm (EX1) shares have bounced back after the company received positive results from its PLEXOVAL II phase one safety study
- During the clinical trial, the company tested its platelet-derived, exosome product Plexaris on 11 enrolled patients
- Results show that all participants remained healthy throughout the study and in the 30-day follow-up period as well
- All induced wounds treated with Plexaris successfully healed without skin defects, abnormal scarring or unusual cosmetic appearance
- Exopharm is up 13.79 per cent and trading at 66 cents per share
Exopharm (EX1) shares have bounced back after the company received positive results from its PLEXOVAL II phase one safety study.
The biopharmaceutical company uses exosomes or extracellular vesicles (EV) from cells to create new, more efficient medicines. During the clinical trial, Exopharm tested its off-the-shelf, platelet-derived EV product Plexaris against wounds on 11 enrolled patients.
Results from the safety study found no untoward or unexpected safety events were reported during the study. All 11 participants remained healthy throughout the study and in the 30-day follow-up period as well.
All induced wounds which were treated with Plexaris successfully healed without skin defects, abnormal scarring, or unusual cosmetic appearance.
Exopharm’s Head of Product Evaluation, Dr Angus Tester, commented on the positive results from the clinical trial, which demonstrated Plexaris’s safety in a cutaneous wound-healing condition.
“The results from this study are very encouraging and are consistent with preclinical testing and the expected safety profile of a purified platelet product,” he said.
In addition to demonstrating Plexaris’ safety as a treatment, the clinical trial also provided the opportunity to show Exopharm’s capabilities in manufacturing a medical-grade product. The clinical-grade doses of Plexaris were produced using the company’s LEAP technology, which can purify EVs on a large scale.
According to Exopharm’s Managing Director, Dr Ian Dixon, 40 clinical-grade doses of Plexaris were made within eight hours by just two staff for the trial. Dr Dixon stated that if the study had been 100 times larger, the process would have taken the same amount of time and labour, only larger equipment.
Exopharm is up 13.79 per cent, trading at 66 cents per share at 2:56 pm AEST.
